Application of 68Ga-labeled ACE2 Targeting Probe PET/CT Imaging in Tracing ACE2 Expression and Diagnosis of Lung Cancer
1 other identifier
interventional
20
1 country
2
Brief Summary
In the past three years, as the key protein suggested to be involved in host cell entry of SARS-CoV-2, studies of ACE2 aroused people's attention again. Tracking the expression of ACE2 in vivo is crucial to further understanding of COVID-19, dynamically monitoring the effect of antiviral therapy and the development of related vaccines. It is also expected to further conduct in-depth research on the physiological effects of ACE2 and RAAS, and the mechanism of ACEI/ARB (32). With the development of both molecular imaging agents and related equipment, several ACE2-targeting PET imaging agents have been investigated based on different strategies while some of them were tested in clinical trials. The aim of this study was to intercept key ACE2-binding sites from coronavirus RBD and test their potential as ACE2-targeting PET agents.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for early_phase_1 lung-cancer
Started Nov 2023
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 30, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 12, 2023
CompletedFirst Submitted
Initial submission to the registry
December 22, 2023
CompletedFirst Posted
Study publicly available on registry
January 8, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2025
CompletedJanuary 8, 2024
November 1, 2023
12 days
December 22, 2023
December 22, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
standardized uptake value (SUV)
comparing the SUVmean of different organs or lesions
through study completion, an average of 1 year
Secondary Outcomes (1)
Diagnostic performance
through study completion, an average of 1 year
Study Arms (1)
68Ga-A3
EXPERIMENTALWithin 1 week, each participant underwent PET/CT scan after intravenous administration of 68Ga-A3
Interventions
Intravenous injection of 68Ga-A3 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-A3 will be used to image organs or lesions which expresses ACE2 by PET/CT.
Eligibility Criteria
You may qualify if:
- the ability to provide informed written consent
- a medical history without any ACE2-related comorbidities
You may not qualify if:
- liver and renal function dysfunction,
- pregnancy or current lactation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Department of Nuclear Medicine, Peking Union Medical College Hopital, Chinese Academy of Medical Science
Beijing, China
Peking Union Medical College Hospital
Beijing, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 22, 2023
First Posted
January 8, 2024
Study Start
November 30, 2023
Primary Completion
December 12, 2023
Study Completion
November 30, 2025
Last Updated
January 8, 2024
Record last verified: 2023-11